Home » Drug Delivery » Injectable Drug Delivery » The Market for Delivering Therapeutic Proteins, 2016-2022

The Market for Delivering Therapeutic Proteins, 2016-2022


market for delivering therapeutic proteins   Published October 2016  •  Catalog no. DTP416K  •  Price US $3,850


Led by the proliferation of antibody-based drugs and candidates, biological drugs as a class continue to outpace all other NCEs in development pipelines and clinical trials. This shift away from small molecule drugs is creating opportunities for drug developers, device designers, packagers and – ultimately – pharmaceutical marketers.
Because biological drugs most often target chronic conditions, dosing strategies and treatment protocols must be developed for long-term use, often for self-administration by patients who may have limitations directly related to their condition. The powerful physiological effects of antibodies, hormones, enzymes and other biological drugs also increase the need for safety and adherence.

Bar_Graph  The Market for Delivering Therapeutic Proteins Report Brochure (Download PDF)

Blue document    The Market for Delivering Therapeutic Proteins Report Order Form (Download PDF)


What You Will Learn

• How are the 280 therapeutic proteins with market authorization from the FDA and EMA currently delivered? What are their as-supplied configurations?
• What are the packaging and delivery strategies by Drug Class? By Market Segment?
• What does the market look like now? What will it look like in 2022?
• Who are the leading participants in the protein delivery technology space? How are they aligned with protein drug developers and suppliers?
• What is the importance of pharma-device alliances and design partnerships on protein drug delivery in terms of product commercialization and market access?
• What is the impact of the global therapeutic protein supply chain on protein product strategies?
• What is the impact of biosimilars on therapeutic drug delivery packaging?
• What are the significant economic, technology, and regulatory factors affecting the market?


The Market for Delivering Therapeutic Proteins, 2016 – 2022 – Summary of Contents

Executive Summary

The Market Opportunity
Drug Development Trends
Unmet Patient Needs
The Changing Role of the Direct Caregiver
Patient Preferences and Self-Administration
Drug Pipelines
The Therapeutic Protein Global Supply Chain

Protein Drug Delivery – Challenges and Limitations
Protein Stability
Lyophilization and Reconstitution
Viscosities and Volumes

Drug Strategies & Therapeutic Protein Packaging
As-Supplied Packaging
Primary Container
Single Use Glass Vials
Multiple Dose Glass Vials
COP Vials
Glass Prefillable Syringes
Disposable Prefilled Pen/Autoinjector
Drug Cartridge for Reusable Pen/Autoinjector
Dual Chamber Cartridges
Dose Prep & Safety Devices
Reconstitution
Needle Protection
Specialty Classes
High Viscosity Devices and Solutions
High Volume Devices and Solutions

Delivering Proteins – Product Analysis by Drug Class
Antithrombins
Blood Factors
Cytokines
Enzymes
Fusion Proteins
G-CSF/GM-CSF
GLP Analogs
Hematopoietics
Hormones
Insulins
Monoclonal Antibodies
Vaccines

The Bottom Line – Market Segment Analysis & Forecasts
Cardiovascular
Diabetes
Hematology
Immunology
Metabolic
Oncology
Orphan
Reproductive

Market Factors
Regulatory Issues
Patient Compliance and Ease of Use
Reimbursement & Managed Care

Company Profiles